What is Inductive Bio?
Inductive Bio operates at the intersection of computational biology and artificial intelligence. The company has developed a sophisticated machine learning platform specifically engineered to accelerate the optimization of small molecule therapeutics. By focusing on the critical drivers of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET), Inductive Bio provides scientists with the predictive modeling necessary to transition from initial compounds to viable development candidates with unprecedented speed and precision. This technological edge positions the firm as a vital player in the digital transformation of drug discovery, addressing the high failure rates and time-intensive nature of traditional laboratory-based screening methods.
How much funding has Inductive Bio raised?
Inductive Bio has raised a total of $29.3M across 2 funding rounds:
Angel/Seed
$4.3M
Series A
$25M
Angel/Seed (2023): $4.3M with participation from Andreessen Horowitz, AlleyCorp companies, Bessemer Venture Partners, and Lux Capital
Series A (2025): $25M led by The Character Group, Andreessen Horowitz, Amino Collective, Lux Capital, Obvious Ventures, and S32
Key Investors in Inductive Bio
Andreessen Horowitz
A prominent private American venture capital firm founded in 2009 that provides comprehensive support to both early-stage startups and established growth-stage enterprises.
Lux Capital
A European-Canadian multi-family office that facilitates strategic growth by connecting enterprises to critical capital, global networks, and executive expertise across the life sciences and technology sectors.
Bessemer Venture Partners
A long-standing venture capital firm with a global footprint, known for its extensive history of backing transformative technology and healthcare companies since 1911.
What's next for Inductive Bio?
With the recent influx of capital, Inductive Bio is poised to transition from its foundational development phase into a period of aggressive scaling. The strategic roadmap likely involves expanding its proprietary datasets and enhancing the predictive accuracy of its ADMET models to support a broader range of therapeutic targets. As the company matures, the focus will shift toward establishing high-value partnerships with global pharmaceutical entities, effectively integrating its ML-driven insights into the standard R&D workflows of the life sciences sector. This growth trajectory suggests a move toward long-term commercialization and the potential for significant disruption in the drug development pipeline.
See full Inductive Bio company page
